Access to extensive donor pool supports LIfT’s move into the clinic London, 03 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’),...

To kick LIfT’s science series off, we spoke to our CEO Alex Blyth regarding what makes IMANs different to regular neutrophils, what were...

London, 13 March 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...

LIfT BioSciences expands into Ireland for manufacturing & clinical operations London, 18 November 2024– LIfT BioSciences, (‘LIfT’ or ‘the...

Award will support clinical manufacturing of the Company’s promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform

LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy